
Sign up to save your podcasts
Or


Credits: 0.25 AMA PRA Category 1 Credit™
Overview: The obesity epidemic has fueled a demand for weight loss medications. Trials have directly compared medications—specifically glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—with a recent study doing just that. Tune in as we explore the evidence comparing semaglutide and tirzepatide for weight loss outcomes up to 1 year.
Episode resource links:
Guest: Alan M. Ehrlich, MD, FAAFP
Thoughts? Suggestions? Email us at [email protected]
By Pri-Med4.5
8383 ratings
Credits: 0.25 AMA PRA Category 1 Credit™
Overview: The obesity epidemic has fueled a demand for weight loss medications. Trials have directly compared medications—specifically glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—with a recent study doing just that. Tune in as we explore the evidence comparing semaglutide and tirzepatide for weight loss outcomes up to 1 year.
Episode resource links:
Guest: Alan M. Ehrlich, MD, FAAFP
Thoughts? Suggestions? Email us at [email protected]

700 Listeners

499 Listeners

102 Listeners

292 Listeners

259 Listeners

3,360 Listeners

1,156 Listeners

194 Listeners

511 Listeners

363 Listeners

254 Listeners

426 Listeners

373 Listeners

317 Listeners

82 Listeners